Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $26.59, for a total value of $398,850.00. Following the transaction, the insider directly owned 409,786 shares in the company, valued at approximately $10,896,209.74. The trade was a 3.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS opened at $26.52 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47. The company has a market cap of $1.55 billion and a P/E ratio of -8.37. The stock has a 50-day moving average of $26.31 and a two-hundred day moving average of $21.44. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00.

Analysts Set New Price Targets

Several equities analysts have commented on KMTS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. BTIG Research assumed coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price objective on the stock. Piper Sandler lifted their target price on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Wells Fargo & Company upped their price target on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.14.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors and hedge funds have recently modified their holdings of KMTS. Quarry LP acquired a new stake in Kestra Medical Technologies in the first quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Kestra Medical Technologies in the 3rd quarter valued at about $48,000. BNP Paribas Financial Markets raised its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares in the last quarter. Brown Brothers Harriman & Co. lifted its stake in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Kestra Medical Technologies in the second quarter valued at approximately $54,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.